Key result
Direct factor Xa inhibitors present a favorable safety and efficacy profile and offer an attractive option for the prevention and treatment of venous and arterial thromboembolism compared to standard therapy.
Factor Xa inhibitors represent a promising class of anticoagulants that do not require routine coagulation monitoring and may replace traditional therapies.
May support direct factor Xa inhibitors for thromboembolism management; leaves open need for prospective trials before practice change.
No takes yet. Share an insight, caveat, or question.
Bondarenko et al. (2013) conducted a review in Venous thromboembolism, atrial fibrillation, and acute coronary syndrome. Factor Xa Inhibitors (e.g., rivaroxaban, apixaban, edoxaban) vs. Conventional antithrombotic therapy (heparins, vitamin K antagonists) was evaluated. Direct factor Xa inhibitors present a favorable safety and efficacy profile and offer an attractive option for the prevention and treatment of venous and arterial thromboembolism compared to standard therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: